Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story |
| |
| Authors: | G. A. Efimov J. M. H. Raats R. G. S. Chirivi J. W. G. van Rosmalen S. A. Nedospasov |
| |
| Affiliation: | 1.National Research Center for Hematology,Ministry of Healthcare of the Russian Federation,Moscow,Russia;2.Engelhardt Institute of Molecular Biology,Russian Academy of Sciences,Moscow,Russia;3.Moscow State University,Moscow,Russia;4.ModiQuest B.V.,AE Oss,The Netherlands;5.Lobachevsky University of Nizhny Novgorod,Nizhny Novgorod,Russia |
| |
| Abstract: | Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
